RESEARCH ARTICLE

Seroprevalence of Enterovirus A71 and Coxsackievirus A16 in Healthy People in Shandong Province, China

Jian-xing Wang1☯, Shuang-li Zhu2☯, Jing Wang1,3☯, Yi Lin1, Yao-ween Pei1, Da-peng Sun1, Yong Zhang2, Xian-jun Wang1, Wen-bo Xu2, Shu-jun Ding1*

1 Institute for Viral Disease Control and Prevention, Shandong Provincial Key Laboratory of Communicable Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan Shandong 250014, China, 2 WHO WPRO Regional Polio Reference Laboratory and Key Laboratory of Medical Virology and Viral Diseases, National Health and Family Planning Commission of China, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China, 3 School of Public Health, Shandong University, Jinan, Shandong 250012, China

☯ These authors contributed equally to this work.
* dsj_jn@126.com

Abstract

Background

Hand, foot, and mouth disease has become very common in mainland of China in recent years, and enterovirus A71 and coxsackievirus A16 are its major etiologic factors. Here we investigated the seroprevalence of enterovirus A71 and coxsackievirus A16 based on a large group of healthy individuals in Shandong province, China.

Methods

A total of 1378 healthy individuals were tested for serum neutralizing antibodies against enterovirus A71 and coxsackievirus A16 using a micro neutralization test.

Results

The overall seroprevalence of enterovirus A71 neutralizing antibodies was 74.75%. It increased significantly from 48.84% in children aged 0–1 years old to 88.64% in those aged 20–29 years (p < 0.01) and decreased to 85.71% in adults > 40 years old with a significant gender-specific difference (p < 0.01). The overall coxsackievirus A16 antibody prevalence was 71.77%. It increased significantly from 39.53% in children aged 0–1 years to 80.68% in those aged 10–19 years (p < 0.01) and decreased to 75.63% in adults >40 years without a gender-specific difference. Nearly 50% of the children <1 year were susceptible to enterovirus A71 infection versus 40% to coxsackievirus A16 infection. Sample collection time and place also played a role in the enterovirus A71 and coxsackievirus A16 positive rates. The overall rates in January were significantly lower than those in April and August (p < 0.01); enterovirus A71 positive rates in Jinan city (capital city of Shandong province) were lower than those in Jining city and Zibo city (p < 0.05); and oxsackievirus A16 positive rates in Jining city were significantly higher than those in Jinan city and Zibo city (p < 0.01).
Conclusion
There were significant differences among age groups, locations, and time points in the sero-prevalence rates of enterovirus A71 and coxsackievirus A16 neutralizing antibodies in healthy people in Shandong province.

Introduction
Hand, foot, and mouth disease (HFMD) was first reported in New Zealand in 1957, and human enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16), members of the Picornaviridae family that were first isolated in 1958 and 1969, respectively [1], are the two major causative agents of HFMD that rarely cause acute neurological symptoms [2–4]. HFMD is a common infectious disease in young children, particularly in those <5 years, that is characterized by brief febrile episodes and a characteristic skin rash with or without oral ulcers, and HFMD outbreaks have been reported in many parts of the world, especially Southeast Asia [5–8]. In mainland of China, owing to a large number of deaths during a short period, HFMD emerged as a serious public health problem since a large HFMD outbreak associated with subgenotype C4 of EV-A71, started in Shandong province, China, in 2007 [9], and then spread throughout the country; in 2008, HFMD was classified as a category C notifiable infectious disease by the Ministry of Health in China. HFMD outbreaks are mainly caused by CV-A16 and/or EV-A71 infections [10–12]. The co-circulation of the two pathogens has been described previously [13–15]. Compared to CV-A16 symptoms, those caused by EV-A71 infection are more severe and lead to more serious complications and even fatalities [4,16,17].

Although immunogenicity in the maternal serum has been examined in some reports [18], the pattern of immune responses against HFMD has not been well studied in mainland of China. In addition, only a few studies of EV-A71 infections have been conducted in Singapore [19–21], Germany [22], Russia [23], Brazil [24], Vietnam [25], Thailand [26], and Cambodia [27]. However, further studies are required with regard to the distribution of immunogenicity against CV-A16 and EV-A71 infectious. This retrospective survey performed in Shandong province, China, aimed to provide fundamental data for the establishment of an immunization program against infection with EV-A71 and CV-A16 and investigate the seroepidemiology of EV-A71 and CA-V16 infections. In this study, a total of 1378 individuals were tested for serum neutralizing antibodies (NtAb) against EV-A71 and CV-A16 using a microneutralization test. Serum samples were collected from healthy people in seven different geographical counties of three cities (Jinan, Jining, and Zibo) in Shandong province in January, April, and August 2010, respectively, with no history of HFMD disease before or during the sample collection.

Methods
Ethics Statement
This study involved no human participants or human experiments. Only serum samples collected from healthy children for public health purposes were used, and written informed consent for the use of their clinical samples was obtained from their parents. This study was approved by the Ethics Committee of Preventive Medicine of Shandong Center for Disease Control and Prevention (Shandong CDC), and the methods were performed in accordance with approved guidelines.
Sample collection

A total of 1378 anonymized samples collected from 1378 healthy individuals (one per subject from 652 males and 756 females, divided into seven different age groups: 0–1, 2–3, 4–9, 10–19, 20–29, 30–39, and >40 years) were tested to detect NtAb against EV-A71 and CV-A16 using a microneutralization test. Serum samples were collected in three cities (Jinan, Jining, and Zibo) in Shandong province in January, April, and August in 2010, respectively. Previous epidemiological studies have indicated that January is generally the low-point of transmission whereas August is generally the peak in northern China [28].

Neutralization test

The neutralization test was performed using a micro technique on a human rhabdomyosarcoma cell line as previously described, with some modifications [20]. Serum samples were initially diluted to 1:8, inactivated at 56°C for 30 minutes, incubated overnight at 4°C, and then diluted from 1:8 to 1:2048. Twenty-five microliters of the virus with a tissue culture infective dose (TCID50) of 100 was mixed with 25 μL of the appropriate serum dilution and incubated at 37°C for 2 hours. Finally, the rhabdomyosarcoma cell suspension (1 × 10^5 cells/mL) was added to the mixture. The plates were then placed in a CO2 incubator at 36°C for 7 days and the potential cytopathogenic effect was determined visually. Cell control, serum control, virus control, and virus back titration were established on each plate. If the back titration showed 32–320 TCID50/well, then the test was considered valid. The EV-A71 strain (evolutionary branch C4a; GenBank accession number: EU703812) used in this study was isolated from a patient with HFMD in Anhui province in 2008 [29], while the CV-A16 strain (evolutionary branch B1b; GenBank accession number: GQ429229) was isolated from a patient with HFMD in Shandong province in 2007 [30]. The lowest dilution at which a cytopathic effect was observed in >50% of wells was considered the antibody titer of the serum sample, and a titer >1:8 was considered the cutoff for a positive antibody response [31–33]. To analyze the immunity level, three NtAb titer ranges were defined: 1:8–1:32 (low), 1:64–1:256 (medium), and 1:512–1:2048 (high).

Statistical analysis

An antibody titer ≥1:8 was considered positive. The chi-square test was used to compare the distribution of NtAb-positive rates of EV-A71 and CV-A16 in different groups categorized by age, gender, specimen collection month, and specimen collection location. We conducted logistic regression analyses to examine the correlations between one main exposure (age, gender, specimen collection month, and specimen collection location) and EV-A71 and CV-A16 seroprevalence with adjustment for the other exposures. Odds ratios (ORs) and corresponding confidence intervals (CIs) for each category, compared with the reference group, were calculated.

Results

Overall EV-A71 and CV-A16 seroprevalence

EV-A71 and CV-A16 infections were widely present in the studied population, although all of the serum samples were collected from individuals who never suffered from HFMD. This result means that asymptomatic EV-A71 and CV-A16 infections are very common. Of the 1378 serum specimens tested in this study, the seropositive rates were 74.75% (1030/1378) for EV-A71 and 71.77% (989/1378) for CV-A16. Moreover, 45%–60% of the children aged <3 years had antibodies to EV-A71, which indicates that almost half of the children were susceptible to the infection (Fig 1 and Table 1).
Fig 1. Age-rated and sex-dependent prevalence of neutralizing antibodies to EV-A71 (upper panel) and CV-A16 (lower panel) in healthy individuals in Shandong province. (Male, blue bars; female, red bars).

doi:10.1371/journal.pone.0162373.g001
No significant difference in seropositive rate was observed between EV-A71 and CV-A16, indicating that the susceptibility to both viruses was the same in all age group. The EV-A71 seropositive rate was significantly higher in females (572/726; 78.79%) than in males (458/652; 70.25%) (p<0.001), and the multivariable logistic regression analyses also supported this conclusion. However, no gender-specific difference was identified in CV-A16 seroprevalence (p>0.05) (Tables 1 and 2). We compared the distribution of EV-A71 seroprevalence by age groups and found that it was 48.84% for those aged <1 year (n = 43), 62.5% for those aged 1–3 years (n = 205), 72.04% for those aged 4–9 years (n = 286), and >82% for all subjects aged >10 years. Compared with those aged <1 year, the seroprevalence was significantly increased in the older age groups, with an OR (95% CI) of 2.7 (1.4–5.2) for those aged 4–9 years, 4.8 (2.4–9.9) for those aged 10–19 years, 8.0 (3.2–19.7) for those aged 20–29 years, 6.1 (2.5–14.9) for those aged 30–39 years, and 6.1 (2.9–12.5) for those aged >40 years; there was no statistically significant difference, excepted for those aged 1–3 years, with an OR (95% CI) of 1.6 (0.8–3.0) (Table 2).

Compared to that observed for EV-A71, the overall seroprevalence of CV-A16 was a little lower in the majority of age groups, but the difference was not statistically significant. There was a significant increase in the CV-A16 seroprevalence from 39.5% among infants <1 year of age to 64.3% for subjects 1–3 years old (p<0.001). Compared with subjects <1 year of age, the

| Table 1. Seroprevalence of HEV71 and CAV16 in healthy people in Shandong province, China. |
|----------------------------------|-----------------|-----------------|-----------------|
|                                  | EV-A71 Serostatus |                  | CV-A16 Serostatus |                  |
| Age, years (%)                   | Negative (n(%))  | Positive (n(%)) | Negative (n(%))  | Positive (n(%))  |
| <1                               | 22 (51.16)       | 21 (48.84)      | 26 (60.47)       | 17 (39.53)       |
| 1–3                              | 123 (37.50)      | 205 (62.50)     | 117 (35.67)      | 211 (64.33)      |
| 4–9                              | 111 (27.96)      | 286 (72.04)     | 110 (27.71)      | 287 (72.29)      |
| 10–19                            | 37 (17.87)       | 170 (82.13)     | 40 (19.32)       | 167 (80.68)      |
| 20–29                            | 10 (11.36)       | 78 (88.64)      | 22 (25.00)       | 66 (75.00)       |
| 30–39                            | 11 (14.29)       | 66 (85.71)      | 16 (20.78)       | 61 (79.22)       |
| >40                              | 34 (14.29)       | 204 (85.71)     | 58 (24.37)       | 180 (75.63)      |
| Overall                          | 348 (25.25)      | 1030 (74.75)    | 389 (28.23)      | 989 (71.77)      |
| Sex                              |                  |                  |                  |
| Male                             | 194 (29.75)      | 458 (70.25)     | 200 (30.67)      | 452 (69.33)      |
| Female                           | 154 (21.21)      | 572 (78.79)     | 189 (26.03)      | 537 (73.97)      |
| doi:10.1371/journal.pone.0162373.t001 |

| Table 2. Multivariable logistic regression of EV-A71 and CV-A16 seroprevalence. |
|----------------------------------|-----------------|-----------------|
|                                  | EV-A71          |                  |
| Variable                        | OR (95% CI)     | P value         |
| Age in years                    |                  |                  |
| <1                              | Reference       |                  |
| 1–3                             | 1.6 (0.8–3.0)   | 0.17            |
| 4–9                             | 2.7 (1.4–5.2)   | 0.003           |
| 10–19                           | 4.8 (2.4–9.9)   | <0.001          |
| 20–29                           | 8.0 (3.2–19.7)  | <0.001          |
| 30–39                           | 6.1 (2.5–14.9)  | <0.001          |
| >40                             | 6.1 (2.9–12.5)  | <0.001          |
| Sex                             |                  |                  |
| Male                            | 0.7 (0.5–0.9)   | 0.01            |
| Female                          | Reference       |                  |
| doi:10.1371/journal.pone.0162373.t002 |
seropositive rate increased in older age groups, with an OR (95% CI) of 2.6 (1.3–5.0) for those aged 1–3 years, 4.1 (2.1–7.9) for those aged 4–9 years, and 6.5 (3.1–13.3) for those aged 10–19 years and then decreased to 4.7 (2.3–9.5) for those >40 years of age. From the results, we can infer that infants <1 year of age were the susceptible population. The peak of the CV-A16 seroprevalence was observed in subjects 10–19 years old, with no further significant decline in the subsequent age groups.

**Titer distribution of NtAb in seropositive individuals and age-dependent immunity to EV-A71 and CV-A16 infections**

To analyze the immunity level, three NtAb titer ranges were defined: 1:8–1:32 (low), 1:64–1:256 (medium), and 1:512–1:2048 (high). Our analysis showed that the distribution of low and medium EV-A71 NtAb titers among the different age groups was inconsistent (Fig 2A). For the low NtAb titer, the percentages of three groups (aged 1–3, 4–9, and 10–19 levels) were <40%, while those of the remaining age groups were all >40% (Fig 2A). In contrast, for the medium NtAb titer, the lowest percentage (26%) was found in the first age group (<1 year), while those of the remaining age groups were all >40% and the subjects 4–9 years had the highest percentage (approximately 55%) (Fig 2A). Unlike the trend observed with low and medium-level titers, high EV-A71 NtAb titers decreased as age increased.

In contrast, most people tested presented with low-level CV-A16 NtAb titers (Fig 2B), especially the <1, 1–3, and 20–29 year age groups. However, patients with medium-level NtAb titers (4–9, 10–19, 30–39 year age groups) comprised >40% of the study population, while those of the remaining groups comprised <40% of the study population, with patients aged <1 and 1–3 years accounting for <30% (Fig 2B). In particular, only a few people demonstrated high CV-A16 NtAb titers (Fig 2B).

**Influence of collection time points and geographic areas**

We conducted a multivariable logistic regression according to specimen collection time and geographic areas to study their influence on the seropositive rate (Table 3). Our results showed that serum specimens collected in January had significantly lower seropositive rates of EV-A71 and CV-A16 NtAb than those of samples collected in April and August (both p < 0.01).

Meanwhile, the seroprevalence of EV-A71 in Jinan city was lower than those observed in Jinjing city and Zibo city (p < 0.05). The seroprevalence of CV-A16 in Jinjing city was higher than that observed in the other two cities (p < 0.05).

**Discussion**

EV-A71 and CV-A16 are the major pathogens associated with sporadic cases and epidemics of HFMD, although 50–80% of infections are asymptomatic. In mainland of China, an outbreak of HFMD occurred in Shandong province in 2007 that was caused by a subgenotype C4 virus of EV-A71. A total of 1149 cases were reported; of them, 970 patients (84.4%) were <5 years old [9]. Nationwide HFMD outbreaks have occurred since 2008 [29], and the HFMD epidemic continues to infect Chinese children <5 years of age every year [28,34,35]. However, CV-A16 could co-circulate with EV-A71, causing very few severe illnesses [36]; EV-A71 seems to be more severe with significantly higher frequencies of serious complications and fatalities [17]. A serologic survey would be useful to understand the level of disease susceptibility and immunity against HFMD among different age groups of people. With NtAb detection, a guide for future immunization programs against HFMD could be developed. This report provides evidence of the improvement of disease monitoring and prediction measures against HFMD.
Our study revealed that the positive rates of NyAb against EV-A71 among children aged <3 years were significantly lower than those of people aged >10 years, while the positive rates of NtAb against CV-A16 among infants aged <1 year were significantly lower than those aged >10 years. With increasing age after 10 years, the positive rates of NtAb against EV-A71 and

---

Fig 2. Titers of NtAb to EV-A71 (Panel A) and CV-A16 (Panel B). Only seropositive individuals of the study are included in the figure.

doi:10.1371/journal.pone.0162373.g002
CV-A16 reached a plateau. Our data also indicate that most EV-A71 infections occur during childhood or early adolescence. Accordingly, the highest antibody titers were observed in these age groups. The low EV-A71 and CV-A16 seroprevalence in the young age groups indicates that infection before the (pre)school years is uncommon. This finding is also supported by the observation that a high proportion of children aged <5 years old were seronegative. The positive immune status for EV-A71 of children reached a steady state in children 4–9 years of age. Furthermore, the number of individuals with a high anti-EV-A71 NtAb level decreased as age increased. In contrast to EV-A71, a high anti-CV-A16 NtAb level was rare in all age groups, indicating that EV-A71 might account for the dominant cases in the HFMD epidemic process.

Immunity to EV-A71 and CV-A16 is mainly dependent on humoral factors, i.e. NtAb formation, although enteroviral infections also induce T-cell immunity [37]. It is currently unclear whether each individual with a low or undetectable NtAb level is susceptible to EV-A71 infection.

In mainland of China, C4a EV-A71 first led to a large-scale HFMD epidemic in Linyi city of Shandong province, where it was first confirmed that EV-A71 induced additional cases of HFMD-related deaths in mainland of China [9]. Previous studies suggested that the EV-A71 strain that caused large-scale HFMD outbreaks with a high number of severe cases and deaths in Fuyang city of Anhui province in 2008 and in Shangqiu city of Henan province in 2009 originated from Linyi city of Shandong province by molecular evolution [38]. Hence, studies on the HFMD epidemic and EV-A71 seroprevalence in Shandong province have a very important position in the history of the HFMD epidemic in mainland of China.

However, Shandong province is located in eastern China with a temperate monsoon climate. In contrast to tropical regions where infections occur at a high incidence throughout the year, HFMD outbreaks and epidemics in Shandong province primarily occur in summer and autumn [28,39]. Our study also found that the serum specimens collected in January (cold season) had significantly lower EV-A71 and CV-A16 NtAb seropositivity rates than those collected in April and August (warm season). These findings are in line with the HFMD epidemic and indicate that the enteroviral infection prevalence is seasonal. In addition to the factor of temperature, some other factors such as school holidays or the beginning of a school term may also be the causes of the formation of seasonal.

In Cambodia in 2012, a HFMD outbreak characterized by severe encephalitis with cardiovascular collapse and pulmonary edema seized international attention and resulted in the deaths of at least 54 children [27] and ultimately, the evolutionary branch C4a EV-A71 was identified as the cause, which is similar to the popular HFMD in mainland of China. Serum samples collected during 2000–2011 were screened for NtAb against EV-A71 and showed that the overall seroprevalence of EV-A71 NtAb was 93.1% (1:8 was set as the cutoff value), which

| Table 3. Multivariable logistic regression of the geometric mean titer for EV-A71 and CV-A16 seropositive individuals. |
|---------------------------------------------------------------|
| **Variable** | **EV-A71** | **CV-A16** |
| | **OR (95% CI)** | **P value** | **OR (95% CI)** | **P value** |
| Month of specimen collection |  |  |  |  |
| January | 0.6 (0.5–0.9) | 0.004 | 0.5 (0.4–0.7) | <0.001 |
| April | 1.3 (1.0–1.9) | 0.08 | 1.0 (0.7–1.4) | 0.93 |
| August | Reference | Reference |  |  |
| Place of specimen collection |  |  |  |  |
| Jinan | 0.7 (0.5–1.0) | 0.04 | 0.9 (0.7–1.2) | 0.53 |
| Jining | 1.1 (0.8–1.5) | 0.55 | 1.5 (1.1–2.0) | 0.01 |
| Zibo | Reference | Reference |  |  |

doi:10.1371/journal.pone.0162373.t003
showed a similar pattern in this study [27]. A number of studies demonstrated the high seroprevalence of EV-A71 NtAb among children several years before and after the large-scale HFMD outbreaks and indicated that the EV-A71 seropositivity rate increased with age but showed no significant sex-specific difference [25,26]. However, the seroprevalence of EV-A71 varies significantly among different regions of the world in countries without large-scale HFMD outbreaks, e.g. the reported EV-A71 seroprevalence was only 12% in subjects 1–4 years of age in Germany [22] and 20.2% in subjects 1–3 years of age in Brazil [40].

Studies have also suggested that geographical differences in EV-A71 and CV-A16 infections in different parts of China, particularly northeast China, where EV-A71 and CV-A16 infections were inactive mainly due to the cold climate, low population density, and other factors [33]. In the same province, the seroprevalence of EV-A71 or CV-A16 may be completely different in different geographic regions. Among the three cities in this study, in 2010, the seropositive rate of EV-A71 in Jinan city was the lowest, while the seropositive rate of CV-A16 in Jining city was the highest. There were no apparent links between EV-A71 seroprevalence and population density due to the three cities with similar population densities. However, the prevalence of EV-A71 and CV-A16 may change after enough susceptible persons were accumulated in the area with lower seropositive rate of the corresponding viruses. Therefore, public health measures to control the spread of EV-A71 and CV-A16 should be devised according to the different regional characteristics of areas in mainland of China [33].

Although EV-A71 (evolutionary branch C4a) [38] and CV-A16 (evolutionary branches B1a and B1b) [30] are widely believed to be the most prevalent serotypes in circulation in mainland of China, this situation may change under certain circumstances. Many other genotypes and subgenotypes of EV-A71 are currently circulating in neighboring countries and regions, and some sporadic importations of other genotypes and subgenotypes of EV-A71 have already been reported [41,42], however, they never became predominant genotypes in mainland of China up to now. Even if this happens, a cross neutralization study with nine EV-A71 strains belonging to nine genotypes and subgenotypes (A, B3, B4, B5, C1, C2, C3, C4, and C5) showed remarkable cross-neutralizing reactivity to these different genotype EV-A71 strains [43] which means C4 subgenotype EV-A71 strain could be used in the seroepidemiology study in mainland of China and can give an true neutralizing antibody levels against all genotypes of EV-A71. However, other serotypes such as CV-A6 were circulating in mainland of China and became the predominant enteroviruses that caused HFMD in 2013 and 2015 [36,44–47]. Inactivated EV-A71 vaccines that developed based on the C4 genotype strain circulating throughout mainland of China were licensed in the end of 2015 [48–50], and will be used to prevent EV-A71–related HFMD in 2016; although an inactivated EV-A71 vaccine derived from C4 subgenotype strain could be effectively used to induce adequate protective immunity against infection by most of the predominant circulating EV-A71 strains [43], it doesn’t work for CV-A6. Thus, a seroprevalence study of other enteroviruses such as CV-A6 using the same serum samples is also very important and can help predict the efficacy of a mass vaccination program that specifically targeted EV-A71.

In conclusion, EV-A71 or CV-A16 infection is very common in Shandong province. Our results were generally consistent with those obtained from neighboring provinces, such as Guangdong, Shanghai, Jiangsu and Anhui [18,32,33,51,52]. This study reflects that herd immunity against EV-A71 infection is lower in young children in Shandong province even after the EV-A71 outbreak in 2007 [9]. Therefore, an immunologic protective barrier cannot be built through natural infection. The significant increases in the HFMD morbidity and mortality have caused an enormous public health burden. Unfortunately, there are no effective drugs against enteroviral infectious, and severe cases often progress very rapidly. Therefore, a safe
and effective vaccine and a targeted effective therapeutic agent against EV-A71 to control EV-A71 outbreaks is urgently needed to reduce EV-A71-related disease burdens and fatalities.

**Acknowledgments**

The authors are grateful to local CDC employees in Shandong province who assisted with the serum samples collection process.

**Author Contributions**

**Conceptualization:** XJW WBX.

**Formal analysis:** JW DPS.

**Funding acquisition:** XJW.

**Investigation:** JXW JW YL YWP DPS.

**Methodology:** JXW SLZ YL YWP YZ XJW WBX SJD.

**Project administration:** XJW WBX.

**Resources:** SLZ YZ XJW WBX SJD.

**Supervision:** SJD.

**Validation:** JXW SLZ JW XJW WBX.

**Writing – original draft:** JXW.

**Writing – review & editing:** SLZ JW YZ SJD.

**References**

1. Pallansch MA, Oberste MS, Whilton JL. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds) Fields Virology, 6th ed Lippincott Williams & Wilkins, Philadelphia: 2013:490–530.

2. Kehle J, Roth B, Metzger C, Pfitzner A, Enders G. Molecular characterization of an Enterovirus 71 causing neurological disease in Germany. J Neurovirol 2003 Feb; 9(1): 126–8. PMID:12587076

3. Wong KT, Lum LC, Lam SK. Enterovirus 71 infection and neurologic complications. N Engl J Med. 2000; 342(5): 356–8. PMID:10660401

4. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med.1999; 341(13): 936–42. PMID:10498488

5. Ahmad K. Hand, foot, and mouth disease outbreak reported in Singapore. Lancet. 2000; 356(9238): 138. PMID:11073035

6. Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999; 354(9191): 1682–6. PMID:10568570

7. Yang F, Du J, Hu Y, Wang X, Xue Y, Dong J, et al. Enterovirus coinfection during an outbreak of hand, foot, and mouth disease in Shandong, China. Clin Infect Dis. 2011; 53(4):400–1. doi: 10.1093/cid/cir346 PMID: 21785005

8. Khanh TH, Sabanathan S, Thanh TT, Thoa le PK, Thuong TC, Hang V, et al. Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg Infect Dis. 2012; 18(12):2002–5. doi: 10.3201/eid1812.120929 PMID: 23194699

9. Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol. 2009; 44(4):262–7. doi: 10.1016/j.jcv.2009.02.002 PMID: 19269888

10. Ooi MH, Wong SC, Podin Y, Akin W, del Sel S, Mohan A, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007; 44(5):646–56. PMID: 17278054
11. Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007; 17(6):371–9. PMID: 17487831

12. Yan JJ, Su JI, Chen PF, Liu CC, Yu CK, Wang JR. Complete genome analysis of enterovirus 71 isolated from an outbreak in Taiwan and rapid identification of enterovirus 71 and coxsackievirus A16 by RT-PCR. J Med Virol. 2001; 65(2):331–9. PMID: 11536241

13. Li L, He Y, Yang H, Zhu J, Xu X, Dong J, et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People’s Republic of China. J Clin Microbiol. 2005; 43(8):3835–9. PMID: 16081920

14. Zhang Y, Xu WB. Molecular epidemiology of enteroviruses associated with hand, foot, and mouth disease in the mainland of China. Biomed Environ Sci. 2013; 26(11):875–6. doi: 10.3967/bes2013.015 PMID: 24331531

15. Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007; 356(12):1226–34. PMID: 17377160

16. Ho M, Chen ER, Hsu KH, Tsu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999; 341(13):929–35. PMID: 10498487

17. Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, et al. Comparison of enterovirus 71 and coxsackievirus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999; 18(12):1092–6. PMID: 10608631

18. Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS One. 2012; 7(5):e37206. doi: 10.1371/journal.pone.0037206 PMID: 22662137

19. Ang LW, Phoon MC, Wu Y, Cutter J, James L, Chow VT. The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect Dis. 2011; 11:270. doi: 10.1186/1471-2334-11-270 PMID: 21988931

20. Ooi EE, Phoon MC, Ishak B, Chan SH. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis. 2002; 8(9):995–7. PMID: 12194783

21. Ang LW, Tay J, Phoon MC, Hsia JP, Cutter J, James L, et al. Seroepidemiology of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus 71 Infections among Children and Adolescents in Singapore, 2008–2010. PLoS One. 2015; 10(5):e0127999. doi: 10.1371/journal.pone.0127999 PMID: 26011735

22. Rabenau HF, Richter M, Doerr HW. Hand, foot and mouth disease: seroepidemiology of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol. 2010; 199(1):45–51. doi: 10.1007/s00430-009-0133-6 PMID: 19941005

23. Akhmadishina LV, Eremeeva TP, Trotsenko OE, Ivanova OE, Mikhailov MI, Lukashev AN. Seroepidemiology and molecular epidemiology of enterovirus 71 in Russia. PLoS One. 2014; 9(5):e97404. doi: 10.1371/journal.pone.0097404 PMID: 24819617

24. Gomes Mde L, de Castro CM, Oliveira MJ, da Silva EE. Neutralizing antibodies to enterovirus 71 in Belem, Brazil. Mem Inst Oswaldo Cruz. 2002; 97(1):47–9. PMID: 11992146

25. Tran CB, Nguyen HT, Phan HT, Tran NV, Wills B, Farrar J, et al. The seroprevalence and seroincidence of enterovirus 71 infection in infants and children in Ho Chi Minh City, Viet Nam. PLoS One. 2011; 6(7):e21116. doi: 10.1371/journal.pone.0021116 PMID: 21765891

26. Linsuwanon P, Puenpa J, Huang SW, Wang YF, Mauleekoonphairoj J, Wang JR, et al. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J Biomed Sci. 2014; 21:16. doi: 10.1186/1423-0127-21-16 PMID: 24548776

27. Horwood PF, Andronicos A, Tarantola A, Saije H, Duong V, Mey C, et al. Seroepidemiology of Human Enterovirus 71 Infection among Children, Cambodia. Emerg Infect Dis. 2016; 22(1):92–5. doi: 10.3201/ eid2201.151323 PMID: 26690000

28. Xing W, Liao Q, Voubod C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014; 14(4):308–18. doi: 10.1016/S1473-3099(13) 70342-6 PMID: 24485991

29. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010; 7:94. doi: 10.1186/1743-422X-7-94 PMID: 20459851

30. Zhang Y, Wang D, Yan D, Zhu S, Liu J, Wang H, et al. Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol. 2010; 48(2):619–22. doi: 10.1128/JCM.02338-09 PMID: 20018819

31. Li W, Yi L, Su J, Lu J, Ke C, Zeng H, et al. Seroepidemiology of Human Enterovirus 71 and Coxsackievirus A16 in Guangdong, China, in Pre- and Post-2010 HFMD Epidemic Period. PLoS One. 2013; 8(12):e80515. doi: 10.1371/journal.pone.0080515 PMID: 24324604
32. Zeng M, El Khatib NF, Tu S, Ren P, Xu S, Zhu Q, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol. 2012; 53(4):285–9. doi: 10.1016/j.jcv.2011.12.025 PMID: 22265829

33. Zhu Z, Zhu S, Guo X, Wang J, Wang D, Yan D, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J. 2010; 7:300. doi: 10.1186/1743-422X-7-300 PMID: 21050463

34. Huang Y, Zhou Y, Lu H, Yang H, Feng Q, Dai Y, et al. Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009–2013. J Med Virol. 2015; 87(9):1471–9. doi: 10.1002/jmv.24200 PMID: 25951788

35. Liu W, Wu S, Xiong Y, Li T, Wen Z, Yan M, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One. 2014; 9(4):e96051. doi: 10.1371/journal.pone.0096051 PMID: 24776922

36. Lim CT, Jiang L, Ma S, James L, Ang LW. Basic reproduction number of coxsackievirus type A6 and A16 and enterovirus 71: estimates from outbreaks of hand, foot and mouth disease in Singapore, a tropical city-state. Epidemiol Infect. 2015;1–7.

37. Juhela S, Hyoty H, Lonnrot M, Roivainen M, Simell O, Ilonen J, et al. Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol. 1998; 54(3):226–32. PMID: 9515773

38. Zhang Y, Wang J, Guo W, Wang H, Zhu S, Wang D, et al. Emergence and transmission pathways of rapidly evolving evolutionary branch c4a strains of human enterovirus 71 in the central plain of China. PLoS One. 2011; 6(11):e28795. doi: 10.1371/journal.pone.0028795 PMID: 22125635

39. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg. 2007; 77(1):188–91. PMID: 17620652

40. Castro CM, Cruz AC, Silva EE, Gomes Mde L. Molecular and seroepidemiologic studies of Enterovirus 71 infection in the State of Para, Brazil. Rev Inst Med Trop Sao Paulo. 2005; 47(2):65–71. PMID: 15880216

41. Yang Q, Zhang Y, Yan D, Zhu S, Wang D, Ji T, et al. Isolation of an imported subgenotype B5 strain of human enterovirus 71 in Chongqing City, China, 2014. Virol J. 2016; 13:115. doi: 10.1186/s12985-016-0571-x PMID: 27357279

42. Fan X, Jiang J, Liu Y, Huang X, Wang P, Liu L, et al. Detection of human enterovirus 71 and Coxsackievirus A16 in an outbreak of hand, foot, and mouth disease in Henan Province, China in 2009. Virus Genes. 2013; 46(1):1–9. doi: 10.1007/s11262-012-0814-x PMID: 23080402

43. Liu L, Mo Z, Liang Z, Zhang Y, Li R, Ong KC, et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 2015; 13:226. doi: 10.1186/s12916-015-0448-7 PMID: 26381232

44. Zeng M, El Khatib NF, Tu S, Ren P, Xu S, Zhu Q, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol. 2012; 53(4):285–9. doi: 10.1016/j.jcv.2011.12.025 PMID: 22265829

45. Liu W, Yi L, Su J, Lu J, Zeng H, Guan D, et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China. Virol J. 2012; 9(1):248.

46. Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016; 15(1):129–37. doi: 10.1586/14760584.2016.1096782 PMID: 26460969

47. Ji H, Li L, Liu Y, Ge H, Wang X, Hu J, et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 among children in Guangdong province, China. BMC Infect Dis. 2013; 13:322. doi: 10.1186/1471-2334-13-322 PMID: 23855481